The Utah Early Neuropathy Scale: a sensitive clinical scale for early sensory predominant neuropathy by Singleton, J. Robinson et al.
RESEARCH REPORT
The Utah Early Neuropathy Scale: a sensitive clinical scale
for early sensory predominant neuropathy
J. Robinson Singleton1, Billie Bixby1, JamesW. Russell2, Eva L. Feldman3, Amanda
Peltier4, Jonathan Goldstein5, James Howard1, and A. Gordon Smith1,6
1Department of Neurology, University of Utah, Salt Lake City, UT; 2Department of Neurology, University of Maryland,
Baltimore, MD; 3Department of Neurology, University of Michigan, Ann Arbor, MI; 4Department of Neurology, Vanderbilt
University, Nashville, TN; 5Department of Neurology, Yale University, New Haven, CT; 6Department Pathology,
University of Utah, Salt Lake City, UT, USA
Abstract Early neuropathy is often sensory predominant and prominently involves
small-diameter nerve fibers. Established neuropathy examination scales such as the Mich-
igan Diabetic Neuropathy Scale (MDNS) and the Neuropathy Impairment Score–Lower
Leg (NIS-LL) focus primarily on large-fiber sensory and motor function. Here, we validate
the Utah Early Neuropathy Scale (UENS), a physical examination scale specific to early
sensory predominant polyneuropathy. Compared with other scales, the UENS emphasizes
severity and spatial distribution of pin (sharp) sensation loss in the foot and leg and
focuses less on motor weakness. UENS, MDNS, and NIS-LL were compared in 215 dia-
betic or prediabetic subjects, with (129) or without neuropathy (86), and repeated in 114
neuropathy subjects after 1 year of follow-up. Neuropathy severity was also evaluated
with nerve conduction studies, quantitative sensory testing, quantitative sudomotor axo-
nal reflex testing, and intraepidermal nerve fiber density determination. The UENS had
a high degree of interrater reliability (interclass correlation of 94%). UENS correlated sig-
nificantly to MDNS and NIS-LL (p , 0.01), and more significantly than MDNS or NIS-LL to
confirmatory tests. In this cohort, UENS had a superior profile to receiver operating char-
acteristic analysis across a range of scores, with a sensitivity (92%) higher than MDNS
(67%) or NIS-LL (81%), without sacrificing specificity. UENS more closely correlated with
change in ancillary and small-fiber neuropathy measures over 1 year follow-up than did
MDNS or NIS-LL. UENS is a sensitive and reproducible clinical measure of sensory and
small-fiber nerve injury and may be useful in trials of early neuropathy.
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Introduction
Neuropathy physical examination scales are fre-
quently used as the primary outcome measure in clinical
trials. A variety of validated scales semiquantitatively
assess sensation, strength, and reflexes. Commonly
used examination scales, such as the Michigan
Diabetes Neuropathy Scale (MDNS) and the lower
extremity portion of the Neuropathy Impairment Score
(NIS-LL), are designed to be applicable across a broad
range of neuropathy types and severity, and balance
contribution of motor and sensory findings to the
examination score. However, this balanced approach
may sacrifice sensitivity to mild neuropathy and the
ability to recognize early neuropathy progression.
These scales lack a mechanism for measuring ana-
tomic spread of sensory loss, an important clinical
aspect of early neuropathy progression.
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Peripheral neuropathy is often recognized by pa-
tients or their physicians at a time when symptoms
outweigh physical signs. Sensory symptoms, pares-
thesias, sensory loss, and neuropathic pain are com-
mon initial complaints (Notermans et al., 1993;
Gorson and Ropper, 1995; The Italian General Practi-
tioner Study Group, 1995). Sensory symptoms and
signs predominate in the most common forms of neu-
ropathy, those related to early diabetes (Dyck and
Dyck, 1999; Feldman et al., 1999), prediabetes
(Novella et al., 2001; Singleton et al., 2001a; 2001b;
Sumner et al., 2003), or idiopathic neuropathy (in
which no clear cause can be identified) (Gorson and
Ropper, 1995; Wolfe and Barohn, 1998; Wolfe et al.,
1999; Smith and Singleton, 2004). Although injury to
all fiber calibers and types occurs, small-diameter
unmyelinated or lightly myelinated nociceptive and
autonomic fibers are often prominently affected in
these common neuropathies (Holland et al., 1998).
There is an increasing interest in recognizing and
treating neuropathy early in its course. Human trials of
rational therapies to slow or reverse diabetic neuropa-
thy, including angiotensin converting enzyme inhibi-
tors, nerve growth factors, and aldose reductase
inhibitors (Greene et al., 1999) have been largely
unsuccessful, despite promising results of these
medications in animal diabetic models (Yagihashi
et al., 2001). One likely contributor to this failure has
been selection of study subjects with relatively
advanced neuropathy (Pfeifer and Schumer, 1995;
Pfeifer et al., 1997). Partly as a consequence of these
criticisms, recent clinical trials of alpha-lipoic acid have
focused on diabetic subjects with new-onset mild dis-
ease (Ziegler et al., 2004).
There is a need for a sensitive clinical examination
scale that more faithfully reflects the small-fiber loss
common in early neuropathy. The Utah Early Neuropa-
thy Scale (UENS) was developed specifically to detect
and quantify early small-fiber sensory neuropathy and
to recognize modest changes in sensory severity and
distribution. We find that the UENS correlates well
with the NIS-LL or MDNS but is more sensitive in
detection of neuropathy.
Materials and Methods
The UENS was performed simultaneously with
the MDNS and NIS-LL and correlated with several
confirmatory measures of neuropathy in a total of 215
study subjects with either diabetes or prediabetes
using American Diabetes Association diagnostic crite-
ria (American Diabetes Association, 2003). Subjects
were participants in one of two National Institutes of
Health-funded studies: Impaired Glucose Tolerance
Neuropathy (IGTN) pilot clinical study (R01 NS40458)
or the Cutaneous Measures of Neuropathy in Diabe-
tes (CMND) study (R01 DK064814). Participant Uni-
versity Institutional Review Boards approved both
studies, and each subject signed a consent form prior
to enrollment. The IGTN study was a three-site (Uni-
versity of Michigan, Yale University, University of
Utah), National Institute of Neurological Disease and
Stroke-funded study designed to characterize the neu-
ropathy associated with IGT, and to develop and
select neuropathy progression measures appropriate
to IGTN. Sixty-nine subjects were enrolled. IGTN sub-
jects were recruited from patients presenting to endo-
crinology or neurology clinics at each university. Most
IGTN subjects (approximately 60) were referred to
neuromuscular clinics for evaluation of otherwise idio-
pathic polyneuropathy and subsequently discovered
to have IGT. The remainder of the subjects were IGT
patients referred to the study from endocrinology or
general medicine clinics when they were recognized
to have a distal polyneuropathy. All IGTN subjects had
clinically evident peripheral neuropathy at the time of
study enrollment.
The CMND study enrolls subjects with diabetes,
with or without early neuropathy. Subjects with
advanced neuropathy (symptoms .5 years) are
excluded. CMND subjects are recruited from a large
community-based primary care network. The Univer-
sity of Utah Health Network (UUHN) includes 10 pri-
mary care clinics in the Salt Lake City metropolitan
area, with more than 300,000 visits yearly. The UUHN
patient database is queried, and informational letters
sent to a random selection of patients of the appropri-
ate age with ICD-9 diagnostic codes consistent with
diabetes. Interested patients respond and are screened
by telephone, then enrolled at an intake visit if they
meet inclusion criteria. The first 146 CMND subjects
enrolled were included in this analysis. Demographic
data for study subjects is provided in Table 2.
Subjects in both study cohorts had identical evalu-
ations for neuropathy, consisting of symptom ques-
tionnaires, focused physical exam scales, nerve
conduction studies (NCS), skin biopsy for intraepider-
mal nerve fiber density (IENFD) determination, quanti-
tative sudomotor axon reflex testing (QSART), and
quantitative sensory testing (QST), described in
greater detail below. The UENS examination form is
reproduced in Fig. 1, together with instructions for its
performance. A safety pin and standard 128 Hz tuning
fork are required to perform the UENS, which takes
about 3 min. Nickel-plated steel, size #2 (4.5 cm, 13/4
inch) safety pins (Grafco #3039-3c; Graham-Field
Health Products) were used for all studies.
The UENS was developed over 2 years using an
iterative process in which individual elements of the
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scale were evaluated for their reliability and sensitiv-
ity. Elements of the UENS adapted from other scales,
such as 0-, 1-, or 2-point scoring for normal, reduced,
and absent vibration or ankle deep tendon reflexes
used in the MDNS, NIS, and NIS-LL (see below), have
been previously validated for reliability.
Cutaneous sharp pain sensation is probably medi-
ated by a combination of unmyelinated c-fiber
Figure 1. Performing the Utah Early Neuropathy Scale (UENS) examination. The UENS requires a number 2 (13/4 inch) safety
pin and a 128 Hz tuning fork. Pin sensation is tested by first reviewing normal sharp sensation to pin on an unaffected portion
of the skin. Once this is established, touch the dorsal surface of the foot and leg with the pin, working centripetally from the
great toe in 1–2 cm increments while asking the subject to respond when they first feel ‘‘any sharpness,’’ and again more
proximally when the pin feels ‘‘as sharp as they would expect.’’ Repeat to firmly establish these levels. On each side, 2 points
are scored for each region in which the patient fails to feel any sharpness. One additional point is scored for each additional
region in which the pin feels less sharp than expected. Only distal sensory loss is scored. So, for instance, a person who
reported absent pin sensation to the mid foot dorsum (4 points) and reduced sensation to the low ankle (1 point) bilaterally
would score a total of 10 points for this portion of the UENS. Vibration is tested by first acquainting the subject with vibration
(as opposed to pressure) sensation, then holding the maximally vibrated tuning fork to the dorsum of the great toe at the distal
interphalangeal joint. Extinction of vibration in less than 10 s is considered ‘‘diminished,’’ while ‘‘absent’’ requires that the
patient cannot detect the maximally vibrating tuning fork at the toe. The motor examination is limited to great toe dorsiflexion.
Other aspects are as typically performed in neurological examination.
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nociceptors, lightly myelinated Ad, and more heavily
myelinated Ab fibers (Lawson, 2005). Twenty-four of
the 42 points in the UENS are devoted to a brief ana-
tomical mapping of sensory loss to pin in the foot and
lower leg. This anatomical concept was adapted from
the examination scale incorporated in the Total Neu-
ropathy Score (Cornblath et al., 1999). Anatomical dis-
tribution of foot and leg segments, as shown in Fig. 1,
were selected for their reproducibility across subjects
(i.e, the boundary between scoring regions can be
readily recognized and standardized to compare one
patient with another), between examiners and over
time. Scoring values for pin sensory loss were chosen
to reflect both partial and complete loss of pin sensa-
tion in each segment to increase sensitivity. Pre-
liminary testing using only complete loss of pin
sensation in each segment found this method less
sensitive to mild defects, but no more reliable
between examiners. Receiver operating characteristic
(ROC) curve analysis showed pin testing alone con-
tributed much of the total sensitivity of the UENS
(data not shown).
The MDNS is a 40-point examination scale devel-
oped and validated for evaluation of diabetic neuropa-
thy (Feldman et al., 1994). Subjects are tested for
strength in finger spread, great toe extension, and
foot dorsiflexion; deep tendon reflexes at biceps, tri-
ceps, patella, and Achilles; sensation is tested with
vibration, 10 g monofilament pressure, and pin sensa-
tion at the great toe. For strength, deep tendon re-
flexes, monofilament, and vibration sensation, 1 point
is given for reduction on either side and 2 points
when the response is absent. For pin sensation at the
great toe dorsum, 2 points per side are assigned if
sharp sensation is absent. The MDNS examination
was originally designed to be paired with NCS to con-
firm peripheral neuropathy but has been used as
a stand-alone measure in clinical trials (Abbott et al.,
1998, Brown et al., 2004). An MNDS score of 6 or
more is necessary to confirm neuropathy.
The NIS-LL represents a focused version of the
full Neuropathy Impairment Score for use in length-
dependent peripheral neuropathy but has also been
combined with electrophysiological tests as a compre-
hensive score (Dyck et al., 1997). Both scales have
been extensively validated, and the NIS-LL has been
used in recent clinical trials of nerve growth factor and
ruboxistaurin in diabetic neuropathy (Apfel et al.,
2000; Tesfaye et al., 2007). For the NIS-LL, all tests
are performed and scored bilaterally. Strength for
ankle and toe dorsiflexion and plantarflexion is graded
on a 4-point scale based on percent weakness. Re-
flexes at knee and ankle are graded 0–2 with correc-
tions for age. Sensation at the distal joint of the great
toe is tested with touch pressure, pin sensation,
vibration, and joint position, and graded 0 (normal), 1
(reduced), or 2 (absent) for each modality. The total
possible bilateral score is 56 (32 motor, 8 reflex, 16
sensory), and no specific diagnostic threshold for neu-
ropathy has been set.
For all study subjects, common alternative causes
of neuropathy were excluded with testing for vitamin
B12, TSH, anti-nuclear antibodies, serum protein elec-
trophoresis, and immunofixation (Smith and Singleton,
2004). Potential subjects with a family history of neu-
ropathy (independent of diabetes) or with a disease
known to be associated with neuropathy (e.g., hepati-
tis C, systemic lupus erythematosis) were excluded.
To test interrater reliability, the UENS was per-
formed on sequential days by two separate blinded
physician examiners for 20 subjects with peripheral
neuropathy. Subjects reported severity of neuropathic
pain using two validated measures, a 100 mm visual
analogue scale (VAS) and the Gracely pain scale (Max
et al., 1992).
For the purposes of calculating sensitivity of
examination scales, subjects were defined as having
polyneuropathy if they had symptoms of neuropathy
confirmed by abnormalities of at least two confirma-
tory electrodiagnostic, electrophysiological, or histo-
logical tests. Symptoms of neuropathy were elicited
by the investigators through direct interview with sub-
jects. Reports of persistent numbness or paresthesias
developing symmetrically in the feet, and progression
from distal to proximal involvement were required his-
torical elements. Examination signs were specifically
excluded from the neuropathy threshold definition
because of concern for a self-referential bias in com-
paring examination scales.
Confirmatory studies were performed in a stan-
dardized fashion for each subject. NCS included left
sural sensory and peroneal motor responses. NCS
were considered abnormal if subjects exhibited any
one or more of the following: low-amplitude sural sen-
sory nerve action potential, low-amplitude peroneal
compound motor action potential, or slowed peroneal
conduction velocity from distal to the fibular head to
ankle. Skin temperature was maintained at .32.0C.
Consistent, age-specific normal values were applied
to all subjects, and in the multicenter IGTN cohort,
NCS results were reviewed for technical quality by
a central laboratory at the University of Michigan.
QST for vibration and cold detection thresholds
was performed at the foot using a CASE IV machine
(WR Medical) and standardized 4.2.1 stepping algo-
rithm. Results were expressed as age-adjusted per-
centiles for detection threshold using a data set
derived from the Rochester Diabetic Neuropathy
Study of Normal Subjects (Dyck et al., 2005) and pro-
vided with the device software by the manufacturer.
Singleton et al. Journal of the Peripheral Nervous System 13:218–227 (2008)
221
Detection thresholds more than the 95th percentile
were considered abnormal.
QSART, a measure of autonomic mediated cuta-
neous sweat production in response to iontophoresed
acetylcholine, was performed at left foot and distal
leg using a QSweat machine (WR Medical) and a stan-
dardized protocol. Sweat volumes at each site were
expressed in microliters and compared with percentile
ranges for age- and sex-adjusted, anatomical site–spe-
cific sweat volumes derived from normal subjects in
the Mayo Clinic Autonomic Reflex Laboratory (Low
and Mathias, 2005), with volumes less than fifth per-
centile judged abnormal.
Three millimeter punch skin biopsies were ob-
tained from the ankle and proximal thigh, fixed, cut in
50-micron-thick sections, stained for the pan-axonal
marker PGP 9.5, and examined microscopically in
a blinded fashion to calculate IENFD according to stan-
dardized counting criteria (Smith et al., 2005). IENFD
at the distal leg was evaluated in considering whether
an abnormality was present.
Statistical analysis
Intraclass correlation coefficients were used to
assess interrater reliability of the UENS. Pearson’s cor-
relation coefficients were used to examine pairwise
correlation between UENS, NIS-LL, MDNS, and other
measures among subjects with neuropathy, both at
baseline, and with change over time. Only subjects
with neuropathy were used in these comparisons to
avoid erroneously improved correlations due to com-
parison of scores in a large subset of subjects with
examination scores at or near zero. Sensitivity and
specificity of examination scales were calculated using
standard formulae, and data for the full spectrum of
possible neuropathy thresholds presented as ROC
curves. Area under the ROC curve, SE, and 95th per-
centile CIs were calculated for each exam scale using
SPSS statistical software (SPSS Inc.). Differences
between correlations of UENS, NIS-LL, and MDNS
with other factors at baseline, and change over 1 year
were assessed using a t test applied to the appropri-
ately transformed difference between two dependent
Pearson correlations (Cohen and Cohen, 1983).
Results
The UENS has an interrater reliability of 94%
across 20 comparisons. Among subjects with neuro-
pathy, initial UENS score closely correlates with that
of the MDNS and NIS-LL (p , 0.001 for each), and
change over 1 year follow-up (p , 0.001 for MDNS,
p ¼ 0.02 for NIS-LL). High reliability and close correla-
tion with these established scales are necessary pre-
requisites for demonstrating the validity of the UENS.
However, compared with MDNS or NIS-LL, the UENS
is significantly more closely correlated with several
ancillary measures of baseline neuropathy severity
(Table 1).
Table 1. Correlation at baseline between examination scales, and with other measures of neuropathy severity in subjects with
neuropathy.*
Exam scales UENS MDNS NIS-LL
UENS ^ 0.895 (,0.001) 0.863 (,0.001)
MDNS ^ ^ 0.880 (,0.001)
NIS-LL ^ ^ ^
Electrophysiology
SSA 0.401 (0.002) 0.319 (0.002) 0.249 (0.033)
PMA 0.354 (0.001) 0.311 (0.004) 0.262 (0.017)
PMCV 0.278 (0.013) 0.183 (0.106) 0.194 (0.087)
CDT 0.270 (0.014) 0.328 (0.002) 0.208 (0.059)
VDT 0.298 (0.006) 0.334 (0.003) 0.306 (0.005)
QSART
Ankle 0.179 (0.105) 0.105 (0.343) 0.068 (0.54)
Foot 0.331 (0.046) 0.087 (0.434) 0.171 (0.123)
IENFD
Distal leg 0.437 (0.001) 0.315 (0.008) 0.186 (0.131)
Distal thigh 0.239 (0.076) 0.210 (0.087) 0.204 (0.132)
Pain
Gracely 0.345 (0.001) 0.279 (0.01) 0.214 (0.124)
VAS 0.360 (0.002) 0.211 (0.076) 0.199 (0.245)
UENS, Utah Early Neuropathy Scale; MDNS, Michigan Diabetic Neuropathy Scale; NIS-LL, Neuropathy Impairment Score^Lower Leg; SSA, sural sensory
amplitude; PMA, peroneal motor response amplitude; PMCV, peroneal motor response proximal conduction velocity; CDTandVDT, cold and vibration detec-
tionthresholds;QSART,quantitative sudomotoraxonreflex testing; IENFD, intraepidermalnerve fiberdensity;VAS,100mmvisualanalogscale.
*Data are expressed as correlation coefficient (p value). Correlation coefficients were compared using a t test applied to the appropriately transformed differ-
ence between two dependent Pearson correlations (Cohen and Cohen, 1983). Measures for which UENSwas significantly (p, 0.05) better correlated than
one other exam scale are shown inbold, and those for which UENSwas significantly better correlated thanbothMDNS andNIS-LL are bolded and italicized. In
contrast,NIS-LLorMDNSwerenot significantlybettercorrelated thanUENSwithanybaselinemeasure.
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The UENS more closely reflects the distribution of
deficits in early sensory neuropathy than does the
MDNS or NIS-LL. Point allocation of the UENS and
MDNS are compared in Fig. 2B. The MDNS allocates
points nearly evenly between tests of sensation,
strength, and deep tendon reflexes. The UENS em-
phasizes sensory loss, and devotes 24 of its 42 points
to an anatomical mapping of pin sensation in the foot
and distal leg. Among our hyperglycemic neuropathy
cohort, pin sensation at the foot is most frequently
abnormal, while ‘‘large-fiber’’ sensory measures
(vibration and joint position) are less often abnormal,
and clinically evident weakness quite rare (Fig. 2A).
This prominent early involvement of small unmyelin-
ated peripheral nerve fibers is also reflected in the
high prevalence of neuropathic pain and reduction in
IENFD. Similar sensory and small-fiber predominance
has been reported in patients with idiopathic neuropa-
thy (Wolfe et al., 1999; Smith and Singleton, 2004).
As shown in Fig. 2B, the allocation of points in
the UENS more accurately reflects the point distribu-
tion among early neuropathy patients. Compared with
the NIS-LL or MDNS, the UENS score more closely
correlates with other measures of neuropathy sever-
ity in subjects with neuropathy and with severity of
neuropathic pain (Table 1). Measures of small-fiber
function (QSART and IENFD) are particularly likely to
correlate with UENS score, reflecting its emphasis on
small-fiber pin sensation.
The UENS has a greater diagnostic sensitivity at
baseline than the MDNS or NIS-LL without sacrificing
specificity. ROC analysis is shown in Fig. 3 together
with areas under the curve, SEs, and 95th percentile
CIs for each measure. UENS demonstrates superior
diagnostic sensitivity and specificity across the spec-
trum of possible scores. Area under the ROC curve
was greater for UENS than for other examination
scales, though this difference did not reach statistical
significance by comparison of SEs.
The UENS was designed to record change in ana-
tomical distribution of pin sensory loss. Over 1 year of
follow-up, change in UENS was significantly corre-
lated with change in both MDNS [correlation coeffi-
cient (cc) 0.758, p , 0.001], and to a lesser degree
NIS-LL (cc 0.425, p ¼ 0.02). Over this short follow-up,
change correlation was not significant for most meas-
ures using any examination scale. However, UENS
change was significantly correlated (p , 0.05) with
change in IENFD at the distal thigh (cc 0.659),
change in neuropathic pain measured by VAS (cc
0.341) and Gracely scales (cc 0.276), and change in
vibration detection threshold (cc 0.262). MDNS
change was significantly correlated only with VAS
change (cc 0.254), while change in NIS-LL correlated
significantly with no other ancillary measure.
Correlation coefficients were not significantly different
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Figure 2. (A) Frequencyofphysical examinationabnormalities
for subjects with hyperglycemic neuropathy from left; sharp
sensation to pin, vibration from 128 Hz tuning fork at the great
toe, traceor absentdeep tendonreflexes, joint positionsenseat
great toe, pressure sensation from 10 g monofilament, and
symmetric distal weakness. Sensory and small-fiber features
predominate. The darkened portion of each bar represents the
proportion of subjects forwhom the examinationmeasurewas
absent. (B) The point distribution of the UENS more closely
reflects the sensory predominance of neuropathic features
seen in early neuropathy than does the MDNS. The pie charts
depict point distribution of the scales on the left: 80% of UENS
points are sensory, compared with 26% of MDNS points.
However, when applied to patients, subscore results are
sensory predominant for both scales. The UENS composition
more closely mirrors the distribution of examination signs
observed in early neuropathy patients. Similar discrepancy is
present with the NIS-LL (data not shown). UENS, Utah Early
Neuropathy Scale; MDNS, Michigan Diabetic Neuropathy
Scale; NIS-LL, Neuropathy Impairment Score–Lower Leg.
Singleton et al. Journal of the Peripheral Nervous System 13:218–227 (2008)
223
UENS was also more likely to record change in
neuropathy severity (either worsened or improved)
in this neuropathy cohort. Fig. 4 compares change in
MDNS or UENS for the 114 neuropathy subjects for
whom 1 year follow-up is available. UENS changed
roughly 2 points for every one point of change in the
MDNS (slope equation with the figure). In most cases
where UENS changed but MDNS did not over 1 year
of follow-up, UENS score change resulted from a
change in the anatomical distribution of pin sensation.
Discussion
There is need for a simple, rapid, reproducible
examination scale targeted to early sensory neuropathy.
Our findings demonstrate that the UENS is a sensitive
and valid measure of early neuropathy and its progres-
sion. The IGTN and CMND subject cohorts are appropri-
ate for an analysis of examination scale sensitivity and
specificity because for each subject, neuropathy has
been extensively confirmed using ancillary electrodiag-
nostic, neurophysiological, and histological testing.
The most striking difference between the MDNS,
NIS-LL, and UENS is the greater sensitivity demon-
strated by UENS. By emphasizing pin (sharp) sensa-
tion, the UENS achieves greater sensitivity to
presence of peripheral neuropathy. Previous studies
indicate that loss of sharp sensation is a common
early feature useful in defining the presence of sen-
sory polyneuropathy (McArthur, 1998; Smith and
Singleton, 2004). Distal reduction in pin sensation was
the most sensitive examination feature of neuropathy
in our study subjects.
The UENS records change in neuropathy severity
in part by mapping the anatomical distribution of pin
sensory loss in the foot and leg. Most patients with
early neuropathy report sensory loss that begins at
the toes or soles of the feet and spreads slowly to
affect proximal foot, then ankle, and lower leg. Con-
versely, resolution of reversible sensory neuropathy
(e.g., following vitamin B12 supplementation) is asso-
ciated with return of sensation first proximally and
then distally in the leg. The UENS is designed to be
sensitive to the changes in anatomic distribution com-
mon to sensory loss early in neuropathy progression.
By comparison, the MDNS and NIS-LL register neu-
ropathy progression primarily when a new sensory
modality (vibration, monofilament pressure) becomes
abnormal.


































Figure 3. Receiver operating characteristic (ROC) curves
demonstrate greater sensitivity and specificity for the UENS
throughout its score. These differences do not reach
statistical significance. UENS, Utah Early Neuropathy Scale.


















Figure 4. Change in the UENS is compared with change in
MDNS over a 1 year follow-up for 114 subjects with hyper-
glycemic neuropathy. Change in the UENS was significantly
correlated to change in the MDNS (p , 0.001) and R2 ¼
0.449. IGTN subjects, all of whom received individualized
diet and exercise counseling, tended to show improved
(lower) scores, while diabetic CMND subjects, who received
no prescribed therapy, showed worsening (higher) scores.
The area of the circles is proportional to the number of
subjects with each combination of score changes. Eighteen
subjects had no change in either score. Linear best fit (solid
line) and 95th percentile CIs (dashed lines) are shown. UENS
changed approximately 2 points for every 1 point change in
MDNS (dUENS ¼ dMDNS(1.94)  0.14). IGTN, Impaired
Glucose Tolerance Neuropathy; CMND, Cutaneous Meas-
ures of Neuropathy in Diabetes; UENS, Utah Early Neuro-
pathy Scale; MDNS, Michigan Diabetic Neuropathy Scale.
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A variety of clinical examination scales for periph-
eral neuropathy are available; some, like the Charcot
Marie Tooth Neuropathy Score, have been validated
for evaluation of a particular neuropathy form (Shy
et al., 2005). Most weigh large-fiber sensory function
and strength similar to the MDNS and many are lon-
ger and more time consuming. The MDNS was vali-
dated against the much more extensive Neuropathy
Impairment Score. Integrated scores range from sim-
ple to very comprehensive. The Michigan Neuropathy
Screening Instrument (MNSI) is a widely used clinical
screening instrument valued for its simplicity. It con-
sists of a brief symptom questionnaire and a sub-
sequent 8-point examination scale (Lunetta et al.,
1998). Two points are assigned bilaterally for abnor-
malities of foot appearance (ulcers, amputations) and
1 point per side (in 0.5-point increments) for abnor-
malities of ankle reflexes or vibration at the great toe.
A score greater than 2 in the setting of a positive
questionnaire indicates neuropathy. The MNSI exami-
nation scale had a significantly smaller ROC curve
area than the other scales evaluated (data not shown),
suggesting this scale is not particularly sensitive to
early neuropathy.
At the other end of the spectrum, the Total Neu-
ropathy Score (TNS) is designed as a comprehensive
neuropathy endpoint that summates symptoms,
signs, and physiology in one score that may be used
as a primary endpoint measure (Cornblath et al.,
1999). It includes an examination scale as well as
points for sensory autonomic and motor symptoms,
QST, and electrophysiological features. Like the
UENS, the TNS factors anatomic distribution of pin
sensory loss as a measure of neuropathy severity.
In general, it is best to choose a neuropathy rating
scale that is specific for the neuropathy severity and
disease being studied. The UENS was designed to
reflect neuropathy severity and change in the narrow
but common subset of patients with early sensory
predominant neuropathy. As such, the UENS would
not be appropriate to the evaluation of neuropathies
with prominent weakness (acute inflammatory demy-
elinating polyradiculoneuropathy) or in those with
more severe disease (advanced diabetic neuropathy).
Instead, for motor and sensory mixed large- and
small-fiber neuropathies of moderate severity, an
examination scale like the NIS-LL or a comprehensive
score like the TNS may be appropriate. These scores
are not ideal for neuropathies of mild severity or for
those involving specific fiber types or functions.
The UENS was designed specifically to meet the
requirements of clinical evaluation in trials of early
Table 2. Baseline demographic andnerve function characteristics of subjects with andwithout neuropathy, using diagnostic criteria
as described in the text.*
No neuropathy, N¼ 86 Neuropathy, N¼129
Two-sided t test, p valueMean SD Mean SD
Subject characteristics
Age 55.8 9.7 57.8 7.1 0.102
% female 50.0 ^ 54.2 ^ 0.578y
Bodymass index 32.4 7.5 34.8 8.3 0.030
Neuropathy measures
Exam scales
UENS 1.39 2.29 9.24 6.10 ,0.001
MDNS 0.83 1.76 6.62 5.13 ,0.001
NIS-LL 0.91 1.82 7.23 5.51 ,0.001
Electrophysiology
SSA 11.6 6.6 5.0 5.4 ,0.001
PMA 4.8 2.2 3.5 2.3 ,0.001
PMCV 44.2 8.2 40.3 5.3 ,0.001
CDT 53.1 27 78.8 23.8 ,0.001
VDT 68.0 23.9 85.3 16.8 ,0.001
QSART
Ankle 1.11 0.77 0.76 0.73 0.001
Foot 0.94 0.72 0.67 0.73 0.008
IENFD
Distal leg 4.6 2.7 1.7 2.3 ,0.001
Distal thigh 6.8 3.51 4.52 2.99 ,0.001
Pain
Gracely 0.24 0.39 0.67 0.53 ,0.001
VAS 6.3 13.8 24.2 27.3 ,0.001
UENS, Utah Early Neuropathy Scale; MDNS, Michigan Diabetic Neuropathy Scale; NIS-LL, Neuropathy Impairment Score^Lower Leg; SSA, sural sensory
amplitude; PMA, peroneal motor response amplitude; PMCV, peroneal motor response proximal conduction velocity; CDT and VDT, cold and vibration
detection thresholds; QSART, quantitative sudomotor axon reflex testing; IENFD, intraepidermal nerve fiber density; VAS, 100 mm visual analog scale.
*Comparison of means for each measure was performed with Student’s t test, and two-sided p values are shown.
yFraction of female subjects in each group was compared using 2  2 contingency table analysis and Fisher’s exact test. Two-sided p value is shown.
Singleton et al. Journal of the Peripheral Nervous System 13:218–227 (2008)
225
neuropathy. Nerve conduction measures of neuropa-
thy severity, such as change in peroneal motor con-
duction velocity or sural sensory amplitude, and direct
histological measures (IENFD, sural nerve biopsy)
have often been used as primary progression meas-
ures in diabetic neuropathy trials because they are
objective, repeatable, and continuously variable. How-
ever, such surrogate measures have been criticized
because they do not directly measure features of neu-
ropathy clinically relevant to the patient (Greene et al.,
1999). The UENS, because of its sensitivity to early
sensory loss and ability to record modest anatomic
change in sensory function, is likely to be useful as
future clinical trials seek to enroll and treat patients
with milder neuropathy.
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